Kenvue
KVUE
Market cap $42.6B

22.20 USD

+0.03

0.14%

Updated Jul 30, 10:36 AM EDT

1 day

0.14%

5 days

-1.64%

1 month

6.07%

3 months

-5.93%

6 months

2.21%

Year to date

4.32%

1 year

18.40%

5 years

-17.47%

10 years

-17.47%

About: Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.

Employees: 22,000

Consumer Staples Household & Personal Products

0

Funds holding %

of 7,323 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

269% more call options, than puts

Call options by funds: $484M | Put options by funds: $131M

123% more first-time investments, than exits

New positions opened: 156 | Existing positions closed: 70

78% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 16 (+7) [Q1 2025]

24% more repeat investments, than reductions

Existing positions increased: 457 | Existing positions reduced: 368

10% more capital invested

Capital invested by funds: $41.1B [Q4 2024] → $45.1B (+$3.99B) [Q1 2025]

7% more funds holding

Funds holding: 997 [Q4 2024] → 1,066 (+69) [Q1 2025]

2.01% less ownership

Funds ownership: 100.44% [Q4 2024] → 98.43% (-2.01%) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

1%

downside

Avg. target

$24

6%

upside

High target

$26

17%

upside

5 analyst ratings

2 positive

40%

3 neutral

60%

0 negative

0%

JP Morgan Andrea Teixeira	17%upside $26	Overweight Maintained	25 Jul 2025
UBS Peter Grom	4%upside $23	Neutral Maintained	17 Jul 2025
Citigroup Filippo Falorni	1%downside $22	Neutral Maintained	15 Jul 2025
Barclays Lauren Lieberman	1%downside $22	Equal-Weight Maintained	15 Jul 2025
B of A Securities Anna Lizzul	13%upside $25	Buy Maintained	15 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about KVUE published over the past 30 days

24/7 Wall Street

4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market

Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.

4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market

Kenvue Increases Quarterly Cash Dividend

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century.

Kenvue Increases Quarterly Cash Dividend

20 Kiplinger July Dividend Favorites: No Cigars

Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to deliver 9-20% net gains by July 2026, with average risk 40% below the market. Many high-yield favorites are not 'safer' due to negative free cash flow, so investors should seek price pullbacks or focus on cash-rich, fair-priced stocks.

20 Kiplinger July Dividend Favorites: No Cigars

Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made availa.

Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

The Motley Fool

Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.

The stock market has historically been a highly effective tool for compounding wealth over time. Another way to use the stock market to achieve your financial goals is to generate income from dividend stocks.

Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.

Proactive Investors

Kenvue announces CEO transition and strategic review

Kenvue (NYSE:KVUE) has announced a CEO transition and the launch of a strategic review process aimed at enhancing shareholder value and improving the long-term performance of the consumer health company. Kirk Perry, a Kenvue director with more than 30 years of experience in the consumer goods and technology sectors, has been appointed interim CEO, effective immediately.

Kenvue announces CEO transition and strategic review

Schaeffers Research

Call Traders Circle Tylenol Parent Amid C-Suite Swap

Tylenol parent Kenvue Inc (NASDAQ:KVUE) is up 1.4% to trade at $21.64, after the company fired its CEO Thibaut Mongon amid efforts to revamp performance.

Call Traders Circle Tylenol Parent Amid C-Suite Swap

Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive Officer Thibaut Mongon has stepped down. Kenvue shares were up by more than 6% during pre-market on the back of the announcement.

Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales

Investors Business Daily

Kenvue Surges After Tylenol-Maker Announces Sweeping Changes

Kenvue stock surged Monday after the company — known for brands like Tylenol — announced sweeping changes, including naming a new CEO.

Kenvue Surges After Tylenol-Maker Announces Sweeping Changes

Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.

The company, formerly part of Johnson & Johnson, says it is taking steps ‘to accelerate profitable growth.'

Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.

See News Rankings

Charts implemented using Lightweight Charts™